Artal Group S.A. Biomarin Pharmaceutical Inc Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$86.68 - $100.3 $2.34 Million - $2.7 Million	-26,939 Reduced 84.27%	5,028 $436,000
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $2.8 Million - $3.75 Million	31,967 New	31,967 $3.11 Million
Q3 2017 Nov 08, 2017	BUY	$80.6 - $94.95 $16.1 Million - $19 Million	200,000	200,000 $18.6 Million

638

178M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.